$KPTI

2 theses

bullish 50%neutral 50%bearish 0%

Avg return (1d)

+2.1%

Win rate (1d)

100% (1 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices delayed ~15 min · refreshed 13m ago

$KPTIr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄neutral

u/Avish_Golakiya · 45d ago31 prior · 63% at 3mo

“Had at $2.04, down 12% to $1.79”

10 penny biotechs I'm watching and slowly adding for September 2026, and the one I got wrong in August.

Drug candidate has priority review and accelerated approval requested with FDA 60-day filing acceptance window, triggering Q4 news cycle. $41M cap against $65M cash is below book value, but short interest surged to 54% of float and 7 months runway create dilution risk before approval payoff.

At post $1.72Now $0.55-68.2% since posted13m ago

1d—

3d-5.8%

1w-7.0%

1m-62.5%

3m—

6m—

1y—

original post →

$KPTIr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/Avish_Golakiya · 78d ago31 prior · 63% at 3mo

10 penny biotechs I'm watching for August 2026, and adding slowly

Karyopharm trades below cash ($46M market cap vs. $91M cash) with an Aug 31 FDA decision on selinexor plus ruxolitinib for myelofibrosis. Despite 80% recent decline and tight runway (~9 months), 35% short float, specialist fund accumulation, and the combination therapy's clinical rationale create asymmetry; dilution risk remains if cash runway extends past approval timeline.

At post $1.91Now $0.55-71.4% since posted13m ago

1d+2.1%

3d+11.0%

1w+6.3%

1m-6.3%

3m—

6m—

1y—

original post →

End of results.